Innovent Announces Oral Presentation at the ESMO Gastrointestinal Cancers Congress 2024 on Latest Clinical Data of Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Cicada Innovations calls for systems approach to ‘turbocharge’ Future Made in Australia act, announces Tech23 cohort
Bridgewest Perth Pharma gains strategic edge with noted Australian Executive John Van Der Wielen on Board
